Foghorn Therapeutics Inc. (FHTX)

Name: Foghorn Therapeutics Inc. (FHTX) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001822462 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Foghorn Therapeutics Inc. reported revenue of $30.91M. Revenue grew 36.8% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $36.74M.

Key ratios (year ended 2025-12-31)

-279.5%

Operating margin

-240.3%

Net margin

36.8%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-01

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Revenue	$36.74M	$30.91M	$22.60M	$34.16M	$19.23M	$1.32M	$430.0K	n/a
R&D Expense	$78.83M	$85.47M	$94.53M	$109.69M	$105.62M	$80.33M	$57.72M	$44.36M
Operating Income	-$72.76M	-$86.39M	-$102.68M	-$107.91M	-$117.14M	-$100.73M	-$68.53M	-$51.08M
Depreciation & Amortization	$2.12M	$3.33M	$3.12M	$3.45M	$3.32M	$3.23M	$1.33M	$693.0K
EBITDA	-$70.64M	-$83.06M	-$99.56M	-$104.45M	-$113.82M	-$97.51M	-$67.20M	-$50.39M
Net Income	-$64.58M	-$74.28M	-$86.62M	-$98.43M	-$108.88M	-$101.32M	-$68.80M	-$51.13M
EPS (Diluted)	n/a	-$1.18	-$1.58	-$2.34	-$2.62	-$2.73	-$6.23	n/a
Total Assets	$203.39M	$198.10M	$283.98M	$285.92M	$404.88M	$519.77M	$255.59M	$22.34M
Total Liabilities	$284.43M	$306.60M	$329.51M	$363.11M	$404.77M	$422.90M	$109.41M	$23.81M
Shareholders' Equity	-$81.04M	-$108.50M	-$45.53M	-$77.19M	$112.0K	$96.87M	$146.19M	-$88.02M
Cash & Equivalents	$68.08M	$80.88M	$55.45M	$80.34M	$52.21M	$101.14M	$92.80M	$14.98M
Operating Cash Flow	-$84.24M	-$86.10M	-$100.41M	-$118.11M	$193.61M	-$50.25M	-$31.29M	-$46.34M
Capital Expenditures	$50.0K	$50.0K	$906.0K	$1.22M	$1.21M	$3.31M	$16.18M	$968.0K
Free Cash Flow	-$84.29M	-$86.15M	-$101.31M	-$119.33M	$192.40M	-$53.56M	-$47.47M	-$47.30M
Shares Outstanding	58.71M	56.66M	55.59M	42.28M	41.80M	41.30M	36.79M	4.87M
Weighted Average Diluted Shares	n/a	62.98M	54.90M	41.97M	41.59M	37.17M	11.05M	n/a
EPS (Basic)	n/a	-$1.18	-$1.58	-$2.34	-$2.62	-$2.73	-$6.23	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView